VV1 (VSV‑IFNβ‑NIS) intratumoral oncolytic virus + PD‑1 blockade (cemiplimab) hits 30% ORR in 1L R/M HNSCC (Simon’s stage 1)

VV1 is an intratumoral oncolytic vesicular stomatitis virus engineered to express IFNβ and NIS (VSV‑IFNβ‑NIS), combined here with the anti–PD‑1 antibody cemiplimab in a Phase 2, Simon two-stage, first-line chemotherapy-free regimen for PD‑L1 CPS≥1 recurrent/metastatic HNSCC (NCT04291105). In stage 1, 10 treated patients had 3 confirmed PRs (ORR 30%) with PR durations of 6.2 and 9.9 months before progression and 1 ongoing PR at 7.7 months; 8/10 had tumor shrinkage (mean −16%; range −57% to +77%). Safety included 4/10 patients with any treatment-related grade ≥3 AE (notably lymphopenia in 3/10; elevated ALK in 1/10) and 1 case of grade 2 immune nephritis responsive to steroids—efficacy looks directionally above the ~15–20% ORR typically seen with first-line PD‑1 monotherapy in PD‑L1–positive disease in KEYNOTE‑048, while grade ≥3 AEs may be higher than PD‑1 monotherapy expectations, though cross-trial comparisons are fragile.